F
Francisco Cruzalegui
Researcher at AstraZeneca
Publications - 33
Citations - 1256
Francisco Cruzalegui is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Triple-negative breast cancer. The author has an hindex of 14, co-authored 33 publications receiving 1060 citations. Previous affiliations of Francisco Cruzalegui include Curie Institute.
Papers
More filters
Journal ArticleDOI
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Bérengère Marty,Virginie Maire,Eléonore Gravier,Guillem Rigaill,Guillem Rigaill,Anne Vincent-Salomon,Marion Kappler,Ingrid Lebigot,Fathia Djelti,Audrey Tourdès,Pierre Gestraud,Pierre Gestraud,Philippe Hupé,Philippe Hupé,Emmanuel Barillot,Emmanuel Barillot,Francisco Cruzalegui,Gordon C. Tucker,Marc-Henri Stern,Jean Paul Thiery,Jean Paul Thiery,John A. Hickman,Thierry Dubois +22 more
TL;DR: The PI3K pathway was found to be activated in BLCs and up-regulated compared with HER2+ tumours as shown by a significantly increased activation of the downstream targets Akt and mTOR (mammalian target of rapamycin).
Journal ArticleDOI
Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer
Virginie Maire,Fariba Nemati,Marion Richardson,Anne Vincent-Salomon,Bruno Tesson,Guillem Rigaill,Eléonore Gravier,Bérengère Marty-Prouvost,Leanne De Koning,Guillaume Lang,David Gentien,Aurélie Dumont,Emmanuel Barillot,Elisabetta Marangoni,Didier Decaudin,Sergio Roman-Roman,Alain Pierré,Francisco Cruzalegui,Stéphane Depil,Gordon C. Tucker,Thierry Dubois +20 more
TL;DR: Observations suggest PLK1 inhibition as an attractive therapeutic approach, in association with conventional chemotherapy, for the management of patients with TNBC.
Journal ArticleDOI
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Virginie Maire,Céline Baldeyron,Marion Richardson,Bruno Tesson,Anne Vincent-Salomon,Eléonore Gravier,Eléonore Gravier,Eléonore Gravier,Bérengère Marty-Prouvost,Leanne De Koning,Guillem Rigaill,Aurélie Dumont,David Gentien,Emmanuel Barillot,Emmanuel Barillot,Emmanuel Barillot,Sergio Roman-Roman,Stéphane Depil,Francisco Cruzalegui,Alain Pierré,Gordon C. Tucker,Thierry Dubois +21 more
TL;DR: TTK is pointed out as a protein kinase overexpressed in TNBC that may represent an attractive therapeutic target specifically for this poor prognosis associated subgroup of breast cancer.
Journal ArticleDOI
Defining actionable mutations for oncology therapeutic development.
T. Hedley Carr,Robert McEwen,Brian Dougherty,Justin Johnson,Jonathan R. Dry,Zhongwu Lai,Zara Ghazoui,Naomi Laing,Darren Hodgson,Francisco Cruzalegui,Simon J. Hollingsworth,J. Carl Barrett +11 more
TL;DR: Some of the different approaches being taken in early clinical development to define actionable mutations are discussed, and a strategy to address this challenge in early-stage exploratory clinical trials is described.
Journal ArticleDOI
S49076 is a Novel Kinase Inhibitor of MET, AXL and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Mike Burbridge,Celine Bossard,Carine Saunier,Imre Fejes,Alain Bruno,Stéphane Léonce,Gilles Ferry,Georges Da Violante,Fraņcois Bouzom,Valérie Cattan,Anne Jacquet-Bescond,Paolo M. Comoglio,Brian P. Lockhart,Jean A. Boutin,Alex Cordi,Jean Claude Ortuno,Alain Pierré,John A. Hickman,Francisco Cruzalegui,Stéphane Depil +19 more
TL;DR: Preclinical studies showing a favorable and novel pharmacologic profile of S49076, a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 are described and a phase I study is currently underway in patients with advanced solid tumors.